ReviewBioMed research international2014
Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial.European journal of nuclear medicine and molecular imaging · 2023Trial
- Dual-modal tumor-selective benzofuran tracer integrating real-time imaging and anticancer effects.Acta pharmaceutica Sinica. B · 2026Article
- Theranostic Smart Bionanosensors for Solid Tumors: Advances, Challenges, and Future Directions.Applied biochemistry and biotechnology · 2026Review
- Stable Chelation of Zr-89 and Ac-225 with Dual Size-Selective Macrocyclic pyInorganic chemistry · 2026Article
- Glypican-3 targeted radiopharmaceuticals for hepatocellular carcinoma: a review of molecular platforms.EJNMMI research · 2026Review
- Tellurium-118 as a novel radionuclide for long-term positron emission tomography.Scientific reports · 2026Article
- Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.EJNMMI radiopharmacy and chemistry · 2026Review
- [BMJ open · 2026Article
- Radioligand-Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis.Molecular diagnosis & therapy · 2026Review
- Development and Preclinical Evaluation of a Zirconium-89-Labeled Immunoconjugate for Positron Emission Tomography Imaging of Leukemia Inhibitory Factor in Glioblastoma.ACS pharmacology & translational science · 2025Article
- The Evaluation of (1Molecules (Basel, Switzerland) · 2025Article
- Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers.European journal of nuclear medicine and molecular imaging · 2025Article
- Synthesis and In Vitro Evaluation of a Scandium-44 Radiolabeled Nanobody as a PD-L1 PET Imaging Probe.Pharmaceutics · 2025Article
- Parametrization of Zirconium for DFTB3/3OB: A Pathway to Study Complex Zr-Compounds for Biomedical and Material Science Applications.Journal of computational chemistry · 2025Article
- [Molecular pharmaceutics · 2024Article
- Development ofMolecular imaging and biology · 2024Article
- Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Review
- Noninvasive PET imaging of tumor PD-L1 expression withAmerican journal of nuclear medicine and molecular imaging · 2024Article
- Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma.Cancer research communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody based positron emission tomography (immuno-PET) imaging is of increasing importance to visualize and characterize tumor lesions. Additionally, it can be used to identify patients who may benefit from a particular therapy and monitor the therapy outcome. In recent years the field is focused on (89)Zr, a radiometal with near ideal physical and chemical properties for immuno-PET. In this review we will discuss the production of (89)Zr, the bioconjugation strategies, and applications in (pre-)clinical studies of (89)Zr-based immuno-PET in oncology. To date, (89)Zr-based PET imaging has been investigated in a wide variety of cancer-related targets. Moreover, clinical studies have shown the feasibility for (89)Zr-based immuno-PET to predict and monitor treatment, which could be used to tailor treatment for the individual patient. Further research should be directed towards the development of standardized and robust conjugation methods and improved chelators to minimize the amount of released Zr(4+) from the antibodies. Additionally, further validation of the imaging method is required. The ongoing development of new (89)Zr-labeled antibodies directed against novel tumor targets is expected to expand applications of (89)Zr-labeled immuno-PET to a valuable method in the medical imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.